A new study by researchers at the University of Illinois Chicago and the University of Pittsburgh suggests that a significant proportion of older patients receiving opioids at dental visits also use psychotropic medications — a potentially harmful combination. Their findings are published in the journal Pharmacotherapy.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have received a $3 million grant from the National Institutes of Health (NIH) to study how SARS-CoV-19 weakens the immune system—and identify drugs to help infected individuals recover. The research will be led by Carl Ware, Ph.D., director of the Institute’s Infectious and Inflammatory Disease Center, and builds on the Institute-wide initiative to develop therapeutics to treat COVID-19.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, Camino Pharma, LLC and University of California San Diego School of Medicine have been awarded an $11.4 million grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) to advance a novel drug candidate for nicotine addiction into first-in-human Phase 1 studies. The drug targets a neuronal signaling pathway underlying addictive behaviors, and would be a first-in-class medication to help people quit smoking.
Commercials from pharmaceutical companies advertising medication to treat psoriasis and eczema lack people from racial and ethnic minorities, according to research from the Perelman School of Medicine at the University of Pennsylvania.
UC San Diego researchers discovered that the SARS-CoV-2 virus can’t grab hold of cell receptor ACE2 without a carbohydrate called heparan sulfate, which is also found on lung cell surfaces — disrupting that interaction with a repurposed drug may help treat COVID-19.
Scientists at Sanford Burnham Prebys, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring. The study, published in EMBO Reports, reveals a promising new therapeutic approach for Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition.
The United States has seen a 200% increase in the rate of deaths by opioid overdose in the last 20 years. But many of these deaths were preventable. Naloxone, also called Narcan, is a prescription drug that reverses opioid overdoses, and in more than 40 states — including Pennsylvania — there is a standing order policy, which makes it available to anyone, without an individual prescription from a healthcare provider.
Scientists announced today that they have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.
Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their medicine as prescribed, say Henry Ford Health System dermatology researchers in a study published in the Journal of the American Academy of Dermatology. Most of these patients are not at any greater risk for COVID-19 than the general population, despite their weakened immune system.
New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020.
Newly published research has reversed our understanding of an aspect of kidney tumor growth. Researchers at Huntsman Cancer Institute at the University of Utah discovered that two key proteins have opposite roles than what was previously believed.
Scientists at the College of Veterinary Medicine have collaborated on a study that pinpoints which specific genes drive – or delay – High-grade serious ovarian carcinoma.
For months, experts have warned against the use of anti-inflammatory medications, such as ibuprofen, to treat COVID-19 symptoms. But could the timing of when this drug is taken play a role in its effectiveness?
A biomedical engineering research team from Tulane University is developing a novel cancer treatment hepatocellular carcinoma, a highly fatal form of liver cancer.
Researchers at the George Washington University have found that the hair loss drug spironolactone is not associated with increased risk of female breast cancer recurrence and may be safe to treat female pattern hair loss in breast cancer survivors. Their findings are published in the Journal of the American Academy of Dermatology.
MD Anderson News Release September 08, 2020 The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
DALLAS – Sept. 9, 2020 – The switch from brand name to generic cholesterol medications that occurred between 2014 and 2018 has saved Medicare billions of dollars, even as the number of people on cholesterol-lowering drugs has increased, UT Southwestern scientists have calculated. Their data, published in the journal JAMA Cardiology, suggest that policymakers and clinicians could help cut Medicare costs even further by switching more patients to generic drugs.
Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering.
Joshua Carter is a co-founder and the CEO of Helix BioStructures, a contract research organization serving the pharmaceutical industry in early-phase drug discovery. Since starting Helix Biostructures in 2017, Carter has leveraged the fast-paced, industrial capabilities of the National Synchrotron Light Source II (NSLS-II)—a U.
New research led by the University of South Australia shows that a blanket approach to prescribing medication during pregnancy may put low birth weight babies at risk for the rest of their lives.
While acetaminophen is helping you deal with your headache, it may also be making you more willing to take risks, a new study suggests. People who took acetaminophen rated activities like “bungee jumping off a tall bridge” as less risky than people who took a placebo.
An innovative genetic study of blood protein levels, led by researchers in the MRC Integrative Epidemiology Unit (MRC-IEU) at the University of Bristol, has demonstrated how genetic data can be used to support drug target prioritisation by identifying the causal effects of proteins on diseases.
UC San Diego researchers report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer’s disease.
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types.
DALLAS – Sept. 3, 2020 – A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor’s growth and spread, UT Southwestern researchers report.
For patients who receive a heart transplant in the near future, the old adage, “Good things come in small packages,” may become words to live by. In a recent study, researchers at Johns Hopkins Medicine and the National Cancer Institute (NCI) demonstrated in mice that they can easily deliver a promising anti-rejection drug directly to the area surrounding a grafted heart by packaging it within a tiny three-dimensional, protein gel cocoon known as a hydrogel. Best of all, the researchers say that the release of the drug is spread out over time, making it highly regulatable and eliminating the need for daily medication to keep rejection in check.
A new technology that uses a protein’s structure to predict the inner wiring that controls the protein’s function and dynamics is now available for scientists to utilize. The tool, developed by researchers at Penn State, may be useful for protein engineering and drug design.
A new international study published today [02 September] has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery.
New findings show that some patients with a rare and aggressive form of leukodystrophy may benefit from receiving treatment with a class of targeted therapy drugs that could improve their neurological function.
Randy Cron, M.D., Ph.D. wrote the first textbook on cytokine storm syndrome in 2019. Cron and UAB's Winn Chatham, M.D., are testing another potential treatment for cytokine storm syndrome in COVID-19: a targeted drug called anakinra.
A class of drugs used for many conditions, including allergies, colds, high blood pressure and depression, may be associated with an increased risk of developing mild thinking and memory problems, particularly in people who have genetic risk factors for Alzheimer’s disease or markers of this condition, according to a study published in the September 2, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.
UC San Diego Health will be part of the Phase III national AstraZeneca clinical trial that will recruit up to 30,000 participants at multiple sites across the country to assess the safety and efficacy of a vaccine to prevent COVID-19.
A new University of Kentucky College of Medicine study provides insight into how a protein called angiotensinogen contributes to blood pressure regulation and atherosclerosis.
In a tremendous demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness.
A study on serotonin, a mood-regulating molecule in the brain that regulates many brain synapses, is helping to unravel the puzzle surrounding its role in autism. The activity and regulation of the serotonin transporter (SERT), protein is critically dependent on a number of other proteins that tell the protein where to locate on nerve cells and how to act. Shifts in the transporter’s activity can significantly impact the ability of serotonin to act in the brain.
As the COVID-19 pandemic continues to put lives and livelihoods at risk, 1 in 2 Americans say they fear a major health event could lead them to file for bankruptcy, marking a 5% increase since 2019.
Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.
Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2).
Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell’s natural “suicide” signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer. A summary of the research, conducted with mice and human cells, appeared Aug. 25 in Cell Reports.
The NCCN Oncology Research Program announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine with research funding provided by Taiho Oncology.
Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.
High school summer students at Brookhaven Lab conduct computational studies, explore inhibitor drugs to disrupt COVID viral proteins that help infectious particles escape from cells.
When the COVID-19 pandemic hit, many students had to rejigger summer plans. Internships they'd expected to be in-person moved to all-virtual formats. For more than 30 students participating in virtual summer programs at the Brookhaven Lab, that disruption presented an opportunity—a chance to engage in research related to the virus responsible for the upheaval.
As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family for the first time; its malfunction is associated with several types of cancer.
DALLAS – Aug. 31, 2020 – Three anticonvulsant drugs commonly used to stop prolonged, potentially deadly seizures each work equally well, according to a national study led by physicians at UT Southwestern. The results provide reassurance to patients who may have drug allergies and to physicians and hospitals that may not have supplies of all three.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right